德琪醫藥(06996.HK)抑制劑聯合單抗藥物治療宮頸癌患者研究初步成果積極
德琪醫藥-B(06996.HK)公布,ATG-008聯合特瑞普利單抗治療複發性或轉移性宮頸癌患者的TORCH-2研究的初步積極成果。
該聯合療法的客觀緩解率(ORR)為52.4%,無論PD-L1表達狀態如何。有關結果乃基於21名接受治療患者的早期數據,其中10名獲得部份緩解(PR),1名獲得完全緩解(CR)。10名有反應者中有5名仍在治療中,而目前病情穩定的2名患者仍在接受治療。
ATG-008是一款口服型mTORC 1/2抑制劑,透過抑制mTOR的活性,進而誘導腫瘤細胞凋亡並降低腫瘤細胞增殖。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.